{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:51:25Z","timestamp":1792547485890,"version":"4.5.0"},"reference-count":85,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372060"],"award-info":[{"award-number":["82372060"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82572330"],"award-info":[{"award-number":["82572330"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2414000"],"award-info":[{"award-number":["2023YFC2414000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2026,4,14]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:p>Transarterial chemoembolisation (TACE) is the standard therapy for intermediate-stage hepatocellular carcinoma (HCC); however, its efficacy is limited by significant tumour heterogeneity. Recent landmark trials (EMERALD-1 and LEAP-012) demonstrated that adding targeted immunotherapy to TACE significantly improves progression-free survival compared with TACE alone. However, the inconsistent overall survival (OS) benefit, particularly in LEAP-012, highlights the necessity for precision patient stratification. Key determinants of outcomes include tumour burden, liver function, microvascular invasion (MVI), systemic inflammation, immune status and comorbidities. For patients with low tumour burden, optimised locoregional therapies can achieve higher complete response rates. For high tumour burden, multimodal strategies are required, with increasing evidence supporting TACE plus targeted therapy with or without immunotherapy. MVI-positive HCC derives added benefit from adjuvant tyrosine kinase inhibitors (TKIs) after TACE, while dynamic liver function monitoring is crucial for safety, especially in patients with Child\u2013Pugh B. Future directions should focus on developing and validating robust multidimensional stratification models. These models should integrate key established determinants\u2014such as tumour burden, liver function reserve, MVI, systemic inflammatory\/immune status, alpha-fetoprotein (AFP) and comorbidities\u2014with promising emerging biomarkers (eg, circulating tumour DNA). Concurrent efforts are needed to optimise combination regimens and conduct health-economic evaluations. Global collaboration and cost-effectiveness analyses are essential to prioritise high-benefit subgroups (eg, those with high tumour burden, MVI positivity and\/or mild inflammation, active immune status alongside preserved liver function and limited comorbidities) for intensive combination therapy while avoiding overtreatment in lower-benefit populations.<\/jats:p>","DOI":"10.1136\/bmjgast-2025-002154","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T13:25:15Z","timestamp":1777987515000},"page":"e002154","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Transarterial chemoembolisation-based combination therapy as a potential new standard for intermediate-stage hepatocellular carcinoma in the targeted immunotherapy era"],"prefix":"10.1136","volume":"13","author":[{"given":"Shuanggang","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujun","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8757-647X","authenticated-orcid":false,"given":"Weijun","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"},{"name":"State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"2026050506250653000_13.1.e002154.1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2025.10.020","article-title":"BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update","volume":"84","author":"Reig","year":"2026","journal-title":"J Hepatol"},{"key":"2026050506250653000_13.1.e002154.2","doi-asserted-by":"crossref","DOI":"10.1016\/j.iliver.2025.100187","article-title":"Debates and progress in the management of intermediate-stage (BCLC stage B) hepatocellular carcinoma","volume":"4","author":"Jiang","year":"2025","journal-title":"ILIVER"},{"key":"2026050506250653000_13.1.e002154.3","doi-asserted-by":"crossref","first-page":"9411","DOI":"10.1097\/JS9.0000000000003138","article-title":"Development and validation of the NTAA prognostic model for BCLC stage B hepatocellular carcinoma undergoing transarterial chemoembolisation: a retrospective multicenter cohort study","volume":"111","author":"Chen","year":"2025","journal-title":"Int J Surg"},{"key":"2026050506250653000_13.1.e002154.4","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02551-0"},{"key":"2026050506250653000_13.1.e002154.5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02575-3"},{"key":"2026050506250653000_13.1.e002154.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0805-y"},{"key":"2026050506250653000_13.1.e002154.7","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0022"},{"key":"2026050506250653000_13.1.e002154.8","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.3748\/wjg.v28.i23.2561","article-title":"Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma","volume":"28","author":"Silk","year":"2022","journal-title":"WJG"},{"key":"2026050506250653000_13.1.e002154.9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-41068-7","article-title":"Surgical resection versus transarterial chemoembolization for patients with hepatocellular carcinoma beyond Milan criteria: prognostic role of tumor burden score","volume":"13","author":"Ho","year":"2023","journal-title":"Sci Rep"},{"key":"2026050506250653000_13.1.e002154.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.03.012"},{"key":"2026050506250653000_13.1.e002154.11","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S1499-3872(16)60089-9","article-title":"Combined hepatectomy and radiofrequency ablation versus TACE in improving survival of patients with unresectable BCLC stage B HCC","volume":"15","author":"Hou","year":"2016","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"2026050506250653000_13.1.e002154.12","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2002.34892"},{"key":"2026050506250653000_13.1.e002154.13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00423-018-1696-8","article-title":"Hangzhou criteria are more accurate than Milan criteria in predicting long-term survival after liver transplantation for HCC in Germany","volume":"403","author":"Qu","year":"2018","journal-title":"Langenbecks Arch Surg"},{"key":"2026050506250653000_13.1.e002154.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70284-5"},{"key":"2026050506250653000_13.1.e002154.15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijsu.2020.07.029","article-title":"Predictors of outcome after liver transplantation for hepatocellular carcinoma (HCC) beyond Milan criteria","volume":"82","author":"Halazun","year":"2020","journal-title":"Int J Surg"},{"key":"2026050506250653000_13.1.e002154.16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/17474124.2018.1417035","article-title":"Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma","volume":"12","author":"Rudnick","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2026050506250653000_13.1.e002154.17","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1148\/radiol.2019181991","article-title":"Radiofrequency Ablation Following Downstaging of Hepatocellular Carcinoma by Using Transarterial Chemoembolization: Long-term Outcomes","volume":"293","author":"Shi","year":"2019","journal-title":"Radiology"},{"key":"2026050506250653000_13.1.e002154.18","doi-asserted-by":"crossref","first-page":"5672","DOI":"10.1097\/JS9.0000000000001752","article-title":"Multimodal imaging-based prediction of recurrence for unresectable HCC after downstage and resection-cohort study","volume":"110","author":"Jiang","year":"2024","journal-title":"Int J Surg"},{"key":"2026050506250653000_13.1.e002154.19","doi-asserted-by":"publisher","DOI":"10.1002\/lt.24169"},{"key":"2026050506250653000_13.1.e002154.20","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.1010824","article-title":"Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis","volume":"10","author":"Si","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"2026050506250653000_13.1.e002154.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02695.x"},{"key":"2026050506250653000_13.1.e002154.22","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70101","article-title":"The Value of no Evidence of Disease (NED) in Intermediate-Stage Hepatocellular Carcinoma After TACE: A Real-World Study","volume":"45","author":"Shen","year":"2025","journal-title":"Liver Int"},{"key":"2026050506250653000_13.1.e002154.23","first-page":"219","article-title":"Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma","volume":"24","author":"Zhang","year":"2018","journal-title":"Diagn Interv Radiol"},{"key":"2026050506250653000_13.1.e002154.24","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2214\/AJR.17.18177","article-title":"Transcatheter Arterial Chemoembolization With or Without Radiofrequency Ablation: Outcomes in Patients With Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma","volume":"210","author":"Hirooka","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"2026050506250653000_13.1.e002154.25","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1080\/02656736.2020.1752400","article-title":"Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis","volume":"37","author":"Chen","year":"2020","journal-title":"Int J Hyperthermia"},{"key":"2026050506250653000_13.1.e002154.26","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3348\/kjr.2018.19.2.237","article-title":"Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas","volume":"19","author":"Zheng","year":"2018","journal-title":"Korean J Radiol"},{"key":"2026050506250653000_13.1.e002154.27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.5152\/dir.2020.19615","article-title":"TACE combined with microwave ablation therapy vs. TACE alone for treatment of early- and intermediate-stage hepatocellular carcinomas larger than 5 cm: a meta-analysis","volume":"26","author":"Liu","year":"2020","journal-title":"Diagn Interv Radiol"},{"key":"2026050506250653000_13.1.e002154.28","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/02656736.2022.2048095","article-title":"Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis","volume":"39","author":"Yang","year":"2022","journal-title":"Int J Hyperthermia"},{"key":"2026050506250653000_13.1.e002154.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00395-0"},{"key":"2026050506250653000_13.1.e002154.30","article-title":"The Combination Strategy of Transarterial Chemoembolization and Radiofrequency Ablation or Microwave Ablation against Hepatocellular Carcinoma","volume":"2019","author":"Xu","year":"2019","journal-title":"Anal Cell Pathol (Amst)"},{"key":"2026050506250653000_13.1.e002154.31","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00261-021-03368-2","article-title":"Comparison of combined transarterial chemoembolization and ablations in patients with hepatocellular carcinoma: a systematic review and meta-analysis","volume":"47","author":"Keshavarz","year":"2022","journal-title":"Abdom Radiol"},{"key":"2026050506250653000_13.1.e002154.32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081084","article-title":"Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study","volume":"11","author":"Kudo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026050506250653000_13.1.e002154.33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000531377","article-title":"A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial","volume":"13","author":"Kudo","year":"2024","journal-title":"Liver Cancer"},{"key":"2026050506250653000_13.1.e002154.34","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1016\/j.acra.2024.04.045","article-title":"Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis","volume":"31","author":"Zhou","year":"2024","journal-title":"Acad Radiol"},{"key":"2026050506250653000_13.1.e002154.35","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1148\/radiol.2018172028","article-title":"Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation","volume":"288","author":"Zhu","year":"2018","journal-title":"Radiology"},{"key":"2026050506250653000_13.1.e002154.36","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318934"},{"key":"2026050506250653000_13.1.e002154.37","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","article-title":"Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial","volume":"2","author":"Meyer","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026050506250653000_13.1.e002154.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"2026050506250653000_13.1.e002154.39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00608"},{"key":"2026050506250653000_13.1.e002154.40","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2147\/JHC.S339379","article-title":"Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma","volume":"8","author":"Huang","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"2026050506250653000_13.1.e002154.41","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2147\/JHC.S431917","article-title":"Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibodies with Hepatic Arterial Infusion Chemotherapy or Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma","volume":"10","author":"Yu","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"2026050506250653000_13.1.e002154.42","doi-asserted-by":"crossref","first-page":"1298122","DOI":"10.3389\/fonc.2024.1298122","article-title":"The safety and efficacy of TACE combined with HAIC, PD-1 inhibitors, and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a retrospective study","volume":"14","author":"Huang","year":"2024","journal-title":"Front Oncol"},{"key":"2026050506250653000_13.1.e002154.43","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1016\/j.acra.2024.09.061","article-title":"Efficacy and Safety of HAIC-FOLFOX Plus Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-line Treatment for Unresectable Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis","volume":"32","author":"Jiang","year":"2025","journal-title":"Acad Radiol"},{"key":"2026050506250653000_13.1.e002154.44","doi-asserted-by":"crossref","first-page":"112711","DOI":"10.1016\/j.intimp.2024.112711","article-title":"Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study","volume":"139","author":"Huang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"2026050506250653000_13.1.e002154.45","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/CMAR.S481242","article-title":"The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma","volume":"17","author":"Wu","year":"2025","journal-title":"Cancer Manag Res"},{"key":"2026050506250653000_13.1.e002154.46","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.10.049"},{"key":"2026050506250653000_13.1.e002154.47","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/cncr.24884","article-title":"Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma","volume":"116","author":"Carr","year":"2010","journal-title":"Cancer"},{"key":"2026050506250653000_13.1.e002154.48","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.acra.2023.07.007","article-title":"Long-term Clinical Outcomes of Yttrium-90 Transarterial Radioembolization for Hepatocellular Carcinoma: A 5-Year Institutional Experience","volume":"31","author":"Makary","year":"2024","journal-title":"Acad Radiol"},{"key":"2026050506250653000_13.1.e002154.49","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1148\/radiol.211806","article-title":"90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial","volume":"303","author":"Dhondt","year":"2022","journal-title":"Radiology"},{"key":"2026050506250653000_13.1.e002154.50","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1007\/s00261-024-04573-5","article-title":"TACE vs. TARE for HCC \u2265\u20098 cm: A propensity score analysis","volume":"50","author":"Phan","year":"2025","journal-title":"Abdom Radiol (NY)"},{"key":"2026050506250653000_13.1.e002154.51","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1158\/1078-0432.CCR-23-0581","article-title":"A Phase I\/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma","volume":"29","author":"Lee","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026050506250653000_13.1.e002154.52","doi-asserted-by":"crossref","unstructured":"Huang J , Niu H , Zhang H , et al . SIRT or TACE in combination with Lenvatinib and PD-(L)1 inhibitor in high tumor burden hepatocellular carcinoma: a multicenter, retrospective, propensity score-matched study. Int J Surg 2025. doi:10.1097\/JS9.0000000000004543","DOI":"10.1097\/JS9.0000000000004543"},{"key":"2026050506250653000_13.1.e002154.53","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1007\/s00464-022-09677-x","article-title":"Influence of Child\u2013Pugh B7 and B8\/9 cirrhosis on laparoscopic liver resection for hepatocellular carcinoma: a retrospective cohort study","volume":"37","author":"Watanabe","year":"2023","journal-title":"Surg Endosc"},{"key":"2026050506250653000_13.1.e002154.54","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-024-13028-5","article-title":"Survival benefit of adjuvant TACE for patients with hepatocellular carcinoma and child-pugh B7 or B8 after hepatectomy","volume":"24","author":"Gao","year":"2024","journal-title":"BMC Cancer"},{"key":"2026050506250653000_13.1.e002154.55","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28337-6","article-title":"Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept","volume":"8","author":"De Lorenzo","year":"2018","journal-title":"Sci Rep"},{"key":"2026050506250653000_13.1.e002154.56","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2340\/1651-226X.2025.42652","article-title":"Patients with uHCC and Child-Pugh B8\/9 also benefit from a combination of antiangiogenic agents and PD-1 inhibitors: a multicenter real-world study","volume":"64","author":"Ding","year":"2025","journal-title":"Acta Oncol"},{"key":"2026050506250653000_13.1.e002154.57","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.adro.2020.01.009","article-title":"Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma in Patients With Child-Pugh B or C Cirrhosis","volume":"5","author":"Lee","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"2026050506250653000_13.1.e002154.58","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17091572","article-title":"The Combined Use of Lenvatinib and Locoregional Therapies for the Management of Hepatocellular Carcinoma","volume":"17","author":"Juthani","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026050506250653000_13.1.e002154.59","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1148\/radiol.2019181818","article-title":"Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma","volume":"292","author":"Peng","year":"2019","journal-title":"Radiology"},{"key":"2026050506250653000_13.1.e002154.60","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamaoncol.2024.1831","article-title":"Survival in Patients With Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial","volume":"10","author":"Fan","year":"2024","journal-title":"JAMA Oncol"},{"key":"2026050506250653000_13.1.e002154.61","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.22.01142","article-title":"Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase III, Randomized Study","volume":"41","author":"Li","year":"2023","journal-title":"JCO"},{"key":"2026050506250653000_13.1.e002154.62","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1148\/radiol.211545","article-title":"Sorafenib Plus Hepatic Arterial Infusion Chemotherapy versus Sorafenib for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis: A Randomized Trial","volume":"303","author":"Zheng","year":"2022","journal-title":"Radiology"},{"key":"2026050506250653000_13.1.e002154.63","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","article-title":"Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion","volume":"5","author":"He","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026050506250653000_13.1.e002154.64","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000466"},{"key":"2026050506250653000_13.1.e002154.65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.08.028"},{"key":"2026050506250653000_13.1.e002154.66","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1043-x"},{"key":"2026050506250653000_13.1.e002154.67","doi-asserted-by":"publisher","DOI":"10.1038\/nmat4997"},{"key":"2026050506250653000_13.1.e002154.68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1897"},{"key":"2026050506250653000_13.1.e002154.69","doi-asserted-by":"crossref","DOI":"10.1136\/bmjonc-2024-000578","article-title":"Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis","volume":"3","author":"Sun","year":"2024","journal-title":"BMJ Oncol"},{"key":"2026050506250653000_13.1.e002154.70","doi-asserted-by":"crossref","first-page":"740","DOI":"10.4103\/jcrt.jcrt_29_21","article-title":"Intermediate stage hepatocellular carcinoma: Comparison of the value of inflammation-based scores in predicting progression-free survival of patients receiving transarterial chemoembolization","volume":"17","author":"Liu","year":"2021","journal-title":"J Cancer Res Ther"},{"key":"2026050506250653000_13.1.e002154.71","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00270-022-03208-w","article-title":"The C-Reactive Protein to Albumin Ratio Is an Independent Prognostic Factor in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: A Large Cohort Study","volume":"45","author":"Li","year":"2022","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2026050506250653000_13.1.e002154.72","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.18632\/aging.202468","article-title":"The lymphocyte-C-reactive protein ratio as the optimal inflammation-based score in patients with hepatocellular carcinoma underwent TACE","volume":"13","author":"Lu","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"2026050506250653000_13.1.e002154.73","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-117","article-title":"Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis","volume":"14","author":"Xiao","year":"2014","journal-title":"BMC Cancer"},{"key":"2026050506250653000_13.1.e002154.74","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.3748\/wjg.v21.i18.5582","article-title":"Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization","volume":"21","author":"Zhou","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2026050506250653000_13.1.e002154.75","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1080\/07357907.2022.2065508","article-title":"Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization Combined With Radiofrequency Ablation","volume":"40","author":"Yang","year":"2022","journal-title":"Cancer Invest"},{"key":"2026050506250653000_13.1.e002154.76","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/jayao.2019.0046","article-title":"Using Pre-Treatment Neutrophil-to-Lymphocyte Ratio to Predict the Prognosis of Young Patients with Hepatocellular Carcinoma Implemented Minimally Invasive Treatment","volume":"9","author":"Sun","year":"2020","journal-title":"J Adolesc Young Adult Oncol"},{"key":"2026050506250653000_13.1.e002154.77","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22999","article-title":"Prognostic significance of the CRP\/Alb and neutrophil to lymphocyte ratios in hepatocellular carcinoma patients undergoing TACE and RFA","volume":"33","author":"Shen","year":"2019","journal-title":"Clinical Laboratory Analysis"},{"key":"2026050506250653000_13.1.e002154.78","doi-asserted-by":"crossref","first-page":"7129","DOI":"10.2147\/OTT.S217935","article-title":"Prognostic significance of lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization and radiofrequency ablation","volume":"12","author":"Shen","year":"2019","journal-title":"Onco Targets Ther"},{"key":"2026050506250653000_13.1.e002154.79","doi-asserted-by":"crossref","first-page":"110228","DOI":"10.1016\/j.intimp.2023.110228","article-title":"The relationship between the efficacy of thermal ablation and inflammatory response and immune status in early hepatocellular carcinoma and the progress of postoperative adjuvant therapy","volume":"119","author":"Chen","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"2026050506250653000_13.1.e002154.80","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118825","article-title":"Using serum \u03b1-fetoprotein for prognostic prediction in patients with hepatocellular carcinoma: what is the most optimal cutoff?","volume":"10","author":"Hsu","year":"2015","journal-title":"PLoS ONE"},{"key":"2026050506250653000_13.1.e002154.81","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00050-9"},{"key":"2026050506250653000_13.1.e002154.82","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3348\/kjr.2018.19.2.237","article-title":"Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas","volume":"19","author":"Zheng","year":"2018","journal-title":"Korean J Radiol"},{"key":"2026050506250653000_13.1.e002154.83","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1080\/02656736.2022.2093413","article-title":"Benefits of step-by-step debulking microwave ablation for huge unresectable hepatocellular carcinoma patients after transcatheter arterial chemoembolization refractoriness","volume":"39","author":"Huang","year":"2022","journal-title":"Int J Hyperthermia"},{"key":"2026050506250653000_13.1.e002154.84","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jhep.2020.11.026","article-title":"Systemic treatment of HCC in special populations","volume":"74","author":"Rimassa","year":"2021","journal-title":"J Hepatol"},{"key":"2026050506250653000_13.1.e002154.85","doi-asserted-by":"crossref","first-page":"505","DOI":"10.5582\/bst.2024.01394","article-title":"Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition)","volume":"18","author":"Tang","year":"2025","journal-title":"Biosci Trends"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2025-002154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T13:25:26Z","timestamp":1777987526000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2025-002154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,5,5]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/bmjgast-2025-002154"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2025-002154","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}